ecancer is a charity with a mission to raise the standards of care for cancer patients across the world through education.https://bsky.app/profile/ecancer.orghttps://bsky.app/profile/ecancer.org/post/3mtxx5bbnvm2lAt #ESMOGI26, Dr Kozo Kataoka discusses GALAXY data showing postoperative ctDNA can identify colorectal liver metastasis patients most likely to benefit from adjuvant chemotherapy. Watch the interview👉 https://bit.ly/4xxdpmA #CRC #ctDNA #MRD #PrecisionMedicine26 Aug 2026 08:47 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mtxx5bbnvm2lhttps://bsky.app/profile/ecancer.org/post/3mtvy2m7nmh25At #ESMOGI26, DrPark Memorial Sloan Kettering Cancer Center discusses GLEAM results. Zolbetuximab + gemcitabine and nab-paclitaxel did not improve survival in CLDN18.2-positive MPC, highlighting the need for better patient selection and combination strategies. Watch the video👉https://bit.ly/3UyJiN625 Aug 2026 13:58 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mtvy2m7nmh25https://bsky.app/profile/ecancer.org/post/3mttoggwiut26At #ESMOGI26, Josep Tabernero discusses that adagrasib plus cetuximab achieved higher response rates, including more CRs, in previously treated KRAS G12C-mutated mCRC, but did not significantly improve PFS or OS vs chemotherapy. Watch the interview👉https://bit.ly/4qxthTJ 24 Aug 2026 16:01 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mttoggwiut26https://bsky.app/profile/ecancer.org/post/3mtswtzxjeb2oAt #ESMOGI26, Dr Michele Milella discusses targeted intratumoural phosphorus-32 microparticles plus FOLFIRINOX in uLAPC, showing encouraging local disease control and supporting further study of this combined approach. Watch the interview👉https://bit.ly/4gPfULa24 Aug 2026 08:59 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mtswtzxjeb2ohttps://bsky.app/profile/ecancer.org/post/3mtlg6ci6sq2uAt #ESMOGI26, Dr Nilo Azad (Hopkins Press) discusses early phase 1 results of dual RAS inhibition with zoldonrasib plus daraxonrasib in heavily pretreated KRAS G12D-mutated metastatic pancreatic cancer, showing encouraging activity and manageable safety. Watch interview👉https://bit.ly/3S6hM9421 Aug 2026 09:12 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mtlg6ci6sq2uhttps://bsky.app/profile/ecancer.org/post/3mtjmloqmls2tAt #EHA2026, Prof Martin Schrappe discusses that blinatumomab improved 4-year EFS to 83% vs 70% with intensive chemotherapy in high-risk paediatric B-ALL, while reducing relapse and severe treatment-related toxicities. Watch the interview👉https://bit.ly/3U8C56h20 Aug 2026 16:01 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mtjmloqmls2thttps://bsky.app/profile/ecancer.org/post/3mtj3vflij625At #EHA2026, Prof Marek Trněný (Charles University) discusses phase 2 CHEPA results showing brentuximab vedotin plus CHP and etoposide achieved a 91% ORR and 76% complete metabolic response rate in previously untreated CD30+ PTCL. Watch the interview👉https://bit.ly/4xlUgny #Lymphoma #Haematology20 Aug 2026 11:03 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mtj3vflij625https://bsky.app/profile/ecancer.org/post/3mth443odne2tAt #EHA2026, Prof Umberto Vitolo discusses phase 3 frontMIND results showing tafasitamab plus lenalidomide and R-CHOP reduced the risk of progression or death by 25% in previously untreated high-risk DLBCL. Watch interview👉https://bit.ly/4cOoYNX #DLBCL #Lymphoma #Haematology19 Aug 2026 16:01 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mth443odne2thttps://bsky.app/profile/ecancer.org/post/3mtgcho6l5a2mAt #EHA2026, Prof Umberto Vitolo discusses updated EPCORE DLBCL-3 results showing fixed-duration epcoritamab achieved a 73% ORR and 63% CR rate in frail, elderly patients with newly diagnosed DLBCL. Watch his interview👉https://bit.ly/4wzkKko #DLBCL #Haematology19 Aug 2026 08:22 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mtgcho6l5a2mhttps://bsky.app/profile/ecancer.org/post/3mtdtwmwjgv2eAt #EHA2026, Prof Anthony Moorman (Newcastle University) discusses UKBlinPredict, using early MRD response and genetic markers such as IKZF1plus and DUX4 rearrangements to predict relapse risk after blinatumomab in B-ALL. Watch the interview👉 https://bit.ly/3RWO6ex #ALL #Haematology18 Aug 2026 08:57 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mtdtwmwjgv2ehttps://bsky.app/profile/ecancer.org/post/3mtc4rrayf62iAt #EHA2026, Prof Carsten Niemann discusses prospective validation of CLL-TIM, a machine-learning model predicting severe infection or treatment need within 2 years in newly diagnosed, asymptomatic CLL. Watch the full interview👉https://bit.ly/4x2NT8x #CLL #Haematology 17 Aug 2026 16:30 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mtc4rrayf62ihttps://bsky.app/profile/ecancer.org/post/3mtbc6chzcj25At #EHA2026, Dr Frederick Chen (Barts Health Archives) discusses UK ITP Registry data showing rapid and robust platelet responses with early romiplostim in acute ITP. Watch the full interview👉https://bit.ly/4cHSLb2 #ITP #Haematology17 Aug 2026 08:34 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mtbc6chzcj25https://bsky.app/profile/ecancer.org/post/3mt2kbarpf42vAt #EHA2026, Prof Chan Cheah discusses phase 3 SOUNDTRACK F1 results showing surovatamig plus rituximab achieved response rates of 95–100% and CR rates of around 84–85% in previously untreated FL. Watch full interview👉 https://bit.ly/3RTR2si #FollicularLymphoma #Haematology14 Aug 2026 16:10 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mt2kbarpf42vhttps://bsky.app/profile/ecancer.org/post/3msztkyy6om2vAt #EHA2026, Prof David Kuter (Harvard Medical School) highlights the fatigue burden experienced by patients with chronic ITP, even when platelet counts are stable and bleeding is minimal. Watch hos full interview here👉 https://bit.ly/4gv8Mn814 Aug 2026 09:24 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3msztkyy6om2vhttps://bsky.app/profile/ecancer.org/post/3msy2n45vlk2hAt #EHA2026, Prof Claire Harrison (Guy's and St Thomas') discusses results showing selinexor & ruxolitinib improved spleen responses in JAK inhibitor-naive MF, with nearly half achieving at least 35% spleen volume reduction & good survival outcomes. Watch the interview here👉 https://bit.ly/3TZ5Xlu 13 Aug 2026 16:25 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3msy2n45vlk2hhttps://bsky.app/profile/ecancer.org/post/3msxjy7ia4j2jAt #EHA2026, Matthew Davids, MD, MMSc discusses phase 3 BRUIN CLL 322 results showing fixed-duration pirtobrutinib plus venetoclax and rituximab improved PFS vs SoC in previously treated CLL/SLL. Watch his interview👉https://bit.ly/4xYnE3x #CLL #Haematology #Oncology13 Aug 2026 11:27 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3msxjy7ia4j2jhttps://bsky.app/profile/ecancer.org/post/3msviu4dfaf2oAt #EHA2026, Prof Fabio Efficace (GIMEMA) discusses the APOLLO trial. Arsenic trioxide plus ATRA improved QoL and reduced fatigue, nausea, vomiting and appetite loss vs chemo in high-risk APL. Watch the interview👉https://bit.ly/4i5qrmt #APL #Haematology #Oncology12 Aug 2026 16:01 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3msviu4dfaf2ohttps://bsky.app/profile/ecancer.org/post/3msuqhwk4or2yAt #EHA2026, Dr Johannes Schetelig (TU Dresden) discusses phase 3 results showing ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation. Watch the full interview👉 https://bit.ly/4wUVxll12 Aug 2026 08:45 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3msuqhwk4or2yhttps://bsky.app/profile/ecancer.org/post/3msswdycjl32oProf Elias Jabbour (UT MD Anderson Cancer Center) reports strong efficacy with subcutaneous blinatumomab in relapsed/refractory Ph+ ALL at #EHA2026. Watch his full interview👉https://bit.ly/45ZSkoJ #ALL #Hematology #Oncology #Immunotherapy11 Aug 2026 15:25 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3msswdycjl32ohttps://bsky.app/profile/ecancer.org/post/3mss5iv7cbt26Prof Liang Wang reports strong efficacy for CD19/CD22 bispecific CAR-T therapy at #EHA2026 for R/R large B-cell lymphoma. Watch the full interview👉https://bit.ly/4fPwfPD #Lymphoma #CART #Hematology #Oncology 11 Aug 2026 08:00 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mss5iv7cbt26https://bsky.app/profile/ecancer.org/post/3msqihdbovx2bAt #EHA2026, Prof Wechalekar (University College London Hospitals NHS Foundation Trust) presents results showing anselamimab reduced all cause mortality and cardiovascular hospitalisations in kappa light chain AL amyloidosis with advanced cardiac disease. Watch the interview👉https://bit.ly/4wXPCMI10 Aug 2026 16:11 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3msqihdbovx2bhttps://bsky.app/profile/ecancer.org/post/3mspx3bkggi2hAt #EHA2026, Dr Ying Huang reports data for CD19/CD20 CAR-T therapy in r/r B-cell lymphoma, showing a favourable safety profile and high response rates, supporting a more accessible off-the-shelf approach to CAR-T. Watch his interview👉https://bit.ly/4fJKZ2w 10 Aug 2026 11:00 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3mspx3bkggi2hhttps://bsky.app/profile/ecancer.org/post/3msiza7zx5k2iAt #EHA2026, Dr Guilherme Perini reports results showing favezelimab plus pembrolizumab improved PFS and DoR vs chemotherapy in PD-1 refractory Hodgkin lymphoma, with similar disease control despite lower response rates. Watch the interview 👉https://bit.ly/4wcq254 #HodgkinLymphoma 07 Aug 2026 16:50 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3msiza7zx5k2ihttps://bsky.app/profile/ecancer.org/post/3msir72r2uk2oAt #EHA2026, Dr Saad Usmani reports study results showing daratumumab plus bortezomib, lenalidomide and dexamethasone improved MRD negativity, response depth and PFS in transplant ineligible newly diagnosed MM, with long term benefit. Watch his interview👉 https://bit.ly/4q2bpjv 07 Aug 2026 14:26 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3msir72r2uk2ohttps://bsky.app/profile/ecancer.org/post/3msfz7q2y7v2pAt #EHA2026, Dr Chiara Sartor reports phase 2 GIMEMA AML2521 results showing venetoclax plus azacitidine achieved high MRD negativity and remission rates in NPM1 mutated AML. Watch her interview👉https://bit.ly/4gf36gP06 Aug 2026 12:11 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3msfz7q2y7v2phttps://bsky.app/profile/ecancer.org/post/3msdvla35zm2yAt #EHA2026, Prof Meletios Dimopoulos reports phase 3 SUCCESSOR-2 results showing mezigdomide plus carfilzomib and dexamethasone significantly improved progression free survival, with higher and deeper responses in relapsed or refractory multiple myeloma, with manageable safety. 05 Aug 2026 16:01 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3msdvla35zm2yhttps://bsky.app/profile/ecancer.org/post/3msd6gknswj26At #EHA2026, Prof Christopher Fox (University of Nottingham) reports results showing epcoritamab improved PFS, complete response rates, and durability of response vs chemoimmunotherapy in R/R large B-cell lymphoma. Watch his interview👉https://bit.ly/4fPd6fs 05 Aug 2026 09:07 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3msd6gknswj26https://bsky.app/profile/ecancer.org/post/3msbgmqittg2wAt #EHA2026, Dr Benoit Tessoulin (@chunantes.bsky.social) presents subgroup analysis from phase 3 EPCORE FL-1 showing epcoritamab plus rituximab and lenalidomide improved response rates and PFS in R/R lymphoma across key patient subgroups👉https://bit.ly/455XIXg 04 Aug 2026 16:28 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3msbgmqittg2whttps://bsky.app/profile/ecancer.org/post/3msakiomwxt2uAt #EHA2026, Prof Martin Wermke (TU Dresden) discusses phase Ia RevSTAR-123 results evaluating AVC-201-01, a first-in-class switchable allogeneic CD123 CAR-T therapy in relapsed/refractory AML. Watch his interview👉https://bit.ly/4xhPbwn #AML #Haematology #CAR_T04 Aug 2026 08:05 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3msakiomwxt2uhttps://bsky.app/profile/ecancer.org/post/3ms6vfydxnm2sAt #EHA2026, Dr Hanny Al-Samkari discusses ITP treatment, including earlier use of thrombopoietin receptor agonists, personalised treatment decisions, and emerging strategies to improve outcomes in ITP and chemotherapy-induced thrombocytopenia👉https://bit.ly/4xik8AC03 Aug 2026 16:15 +0000at://did:plc:v2bbfxjs2fopw6y76ibai2cd/app.bsky.feed.post/3ms6vfydxnm2s